6 July 2020

IMS CORE lab teams up with Cristal Therapeutics

Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.

Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, ​where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.​ 

The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.

For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/

Cancer cells

Also read: 

  • Peter Peters corana image

    How the coronavirus infects our small intestines

    Monday, May 18, 2020

    Interview with prof. Peter Peters on the Science article he co-worked on intensively.

    Read more
  • corona virus

    Coronavirus SARS-CoV-2 infects cells of the intestine

    Friday, May 1, 2020

    Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that the coronavirus SARS-CoV-2, which causes COVID-19, can infect cells of the intestine and multiply there.

    Read more

  • Prof. Maarten Honing joins Dutch Chemistry Council

    Monday, March 2, 2020
    Read more